RxDoctor Payments Data

Samer Kheirbek, MD

Critical Care Medicine · Dearborn, MINPI 1679664106

Payments from drug & device makers

$525in general payments, 2019–2025

Across 25 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$162
  • GSK$139
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$78
  • Regeneron Healthcare Solutions, Inc.$46
  • ANI Pharmaceuticals, Inc.$32
  • Pulmonx Corporation$29
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$525 in reported general payments places this provider in the 55th percentile of 177 critical care medicine providers in Michigan.

See all critical care medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$241,733
Medicare patients
676
Services billed
1,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter173$129,750
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$22,235
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$20,718
Spiriva RespimatTiotropium Bromide15$15,208
Breo ElliptaFluticasone/Vilanterol23$11,975
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$6,460
Albuterol Sulfate HfaAlbuterol Sulfate142$5,401
SymbicortBudesonide/Formoterol Fumarate15$4,361
Ventolin HfaAlbuterol Sulfate41$2,270
Montelukast Sodium112$2,219
Fluticasone Propionate30$1,988
Valsartan14$203
Methylprednisolone33$193
Prednisone11$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$139$163,960235 claims
AstraZenecaBreztri Aerosphere, Symbicort$162$25,07944 claims
ANI Pharmaceuticals, Inc.Valsartan$32$20314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 177 critical care medicine providers in Michigan.

Other critical care medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →